• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Human Genome Sciences

Human Genome Sciences

  1. All
  2. Morningstar Articles
  3. Investing
  4. Research
  1. Is It Time for the Fed to ‘Level’ With Markets?

    Human Genome Sciences' two big drugs could make up for years of losses.

  2. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  3. Health-Care Investing Alive and Well

    Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.

  4. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

  5. The Market's Most Overvalued Stocks

    Equity valuations as a whole have barely budged in 2005, but the market remains a bit on the pricey side when comparing to Morningstar's collective fair value estimates (To see more on Morningstar's perspective on market valuations, check out our Market Valuation Graph ). The median stock in our ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.